Effect of multistrain probiotics on symptom severity in irritable bowel syndrome: a systematic review and meta-analysis of irritable bowel syndrome-symptom severity score outcomes
Abstract
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with varying symptom severity. Although probiotics are frequently used for IBS management, the effects of multistrain probiotic interventions on IBS symptom severity, as measured by the IBS symptom severity score (IBS-SSS), remain unclear. This systematic review, conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, compared multistrain probiotics with placebo in patients with IBS, focusing on IBS-SSS outcomes. Risk of bias was assessed using the Risk of Bias 2.0 tool, and meta-analysis was performed with Review Manager 5.4.1. From the 1858 screened records, 12 studies involving 1303 participants were included. Multistrain probiotics significantly reduced total IBS-SSS scores [mean difference = -43.66, 95% confidence interval (CI): -65.89 to -21.44, P = 0.0001, I ² = 99%]. Significant improvements were also found in IBS-SSS subscores, including number of days with pain (mean difference = -7.38, 95% CI: -11.86 to -2.89, P = 0.001, I ² = 100%), bloating (-5.62, 95% CI: -10.76 to -0.48, P = 0.03, I ² = 100%), bowel habit satisfaction (-11.90, 95% CI: -19.21 to -4.59, P = 0.001, I ² = 99%), and quality of life (QoL) (-11.99, 95% CI: -16.3 to -7.60, P < 0.00001, I ² = 91%); however, changes in abdominal pain scores and IBS-specific QoL were not statistically significant. High heterogeneity prompted sensitivity analyses to identify contributing…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,303 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.